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Abstract Genostem (acronym for “Adult mesenchymal
stem cells engineering for connective tissue disorders.
From the bench to the bed side”) has been an European
consortium of 30 teams working together on human bone
marrow Mesenchymal Stem Cell (MSC) biological proper-
ties and repair capacity. Part of Genostem activity has been
dedicated to the study of basic issues on undifferentiated
MSCs properties and on signalling pathways leading to the
differentiation into 3 of the connective tissue lineages,
osteoblastic, chondrocytic and tenocytic. We have
evidenced that native bone marrow MSCs and stromal
cells, forming the niche of hematopoietic stem cells, were
the same cellular entity located abluminally from marrow
sinus endothelial cells. We have also shown that culture-
amplified, clonogenic and highly-proliferative MSCs were
bona fide stem cells, sharing with other stem cell types the
major attributes of self-renewal and of multipotential
priming to the lineages to which they can differentiate
(osteoblasts, chondrocytes, adipocytes and vascular smooth
muscle cells/pericytes). Extensive transcription profiling
and in vitro and in vivo assays were applied to identify
genes involved in differentiation. Thus we have described
novel factors implicated in osteogenesis (FHL2, ITGA5,
Fgf18), chondrogenesis (FOXO1A) and tenogenesis
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(Smad8). Another part of Genostem activity has been
devoted to studies of the repair capacity of MSCs in animal
models, a prerequisite for future clinical trials. We have
developed novel scaffolds (chitosan, pharmacologically
active microcarriers) useful for the repair of both bone
and cartilage. Finally and most importantly, we have shown
that locally implanted MSCs effectively repair bone,
cartilage and tendon.
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Genostem, acronym for “Adult mesenchymal stem cells
engineering for connective tissue disorders. From the bench
to the bed side” has been an European Integrated Project
sponsored for 4 years by the European Community. It has
included 30 teams, belonging to different European
countries and to Israel, working together from the begin-
ning of 2004 to the end of 2007.
This review highlights the essential scientific data
provided by the consortium.
Cellular and Molecular Aspects
Approximately half of Genostem activity has been dedicat-
ed to the study of basic issues concerning bone marrow
MSCs, the properties of undifferentiated MSCs and the
signalling pathways leading to the differentiation into 3 of
the connective tissue lineages, osteoblastic, chondrocytic
and tenocytic.
Proliferating Human Bone Marrow MSCs
Contrary to bone marrow native cells, that remain quiescent
in vivo, MSCs actively proliferate once seeded in appro-
priate medium. Many attributes of the proliferating cells
remain controversial to the point that the cell denomination
varies from one author to the other (mesenchymal stem, or
progenitor, or stromal cells, skeletal stem cells, stromal
stem cells….). In Genostem, we have retained the term
Mesenchymal Stem Cells for the population of human bone
marrow cells culture amplified in standardized conditions
and whose attributes are described below.
Standardization of the Culture System
Standardisation of the culture system for ex vivo amplifi-
cation was a pre-requisite to our work so that results could
be compared between labs. Standards for the culture system
included the use of alpha-MEM without nucleotides and of
fetal calf serum selected for cell growth, and a cell seeding
concentration of 5×104 cells/cm2 at culture initiation and of
103/cm2 at each passage [1]. Fibroblast growth factor-2
(FGF-2) increased the growth of MSCs in elderly patients
(>60 years old), but not in children or younger adults [2].
FGF-2 was therefore added at low concentration (1 ng/mL
twice a week at medium renewal) in culture of elderly
patients.
Proliferation Potential
How primary layers are generated, to which extent do cells
proliferate and which factors are implicated in MSC
proliferation remained largely unknown and controversial.
Studies in Genostem have addressed these issues.
Using large-scale Taqman Low-Density Array based on
qRT-PCR, we have compared the expression level of 300
transcripts in passage 1 primary layers and in fast-growing
clones developed at culture initiation and grown for a
similar amount of time than primary layers. Gene expres-
sion levels were similar in intensity and in distribution
among primary layers and most of the clones [3]. This
congruence of expression suggests that fast-growing clones
can be taken as representative of the cell population found
in primary layers. Whereas establishing primary cultures at
non-clonal density results in an initially heterogeneous
population of cells with variable potential for growth, it is
likely that a subset of fast-growing cells becomes selected
over time in culture and passaging, leading to a progressive
increase in culture homogeneity.
Although MSCs actively proliferate in vitro, we have
shown that their proliferation potential remains within the
Hayflick’s limit of 50 population doublings (PDs). About 1/
3 of the clones generated at culture inception reached more
than 23–25 PDs, whereas clones developed later (at the end
of P0 and P1) showed growth arrest after 18–20 PDs [3].
The transcripts for telomerase reverse transcriptase (TERT)
was not detected, which is in agreement with the limited,
albeit large, proliferation potential.
Genostem teams have begun to unravel the network of
cytokines and transcription factors controlling MSC prolif-
eration [3, 4]. Part of this network is shown on Fig. 1; it
underscores the potential role of the cytokines IL6 and
NRG1 and of the transcription factors GATA6, GATA2 and
ZFMP2.
We have also searched for factors selecting for highly
proliferative clonogenic cells. Pre-treatment of cultures with
antibodies neutralizing interferon-alpha (IFNA), or directed
against its receptor, resulted in a marked increase in the
number of very large and fast-growing colonies obtained in
the presence of low, but necessary, concentrations of FGF-2
[4]. Blockade of the interferon-alpha pathway may be a
substitute for “competence growth factor”, with FGF-2
acting as “progression growth factor”. These data indicate
that inhibition of the IFNA pathway is a way to increase the
Stem Cell Rev and Rep (2011) 7:32–42 33
recruitment of clonogenic cells with high proliferative
capacity.
Phenotype
In many publications MSCs are characterized mainly by their
membrane phenotype. Studies in Genostem have shown that
no single marker was specific for bonemarrowMSCs, but that
a large set of markers was required to characterize this cell
population. MSC phenotype specificity has been defined by a
set of 113 transcripts out of 1624 molecules coding for plasma
membrane proteins inventoried in Affymetrix microarrays [5].
This set includes 20 Clusters of Differentiation (CD), 17 of
which were studied by flow cytometry at the protein level
and were expressed at the plasma membrane. This set allows
the identification of a mesenchymal phenotype clearly
distinct from the hematopoietic/endothelial phenotypes
(largely predominant in the bone marrow), and from the
other skeletal mesenchymal cell populations (periosteal cells
and synovial fibroblasts) [5, 6].
Another current issue was whether some of the markers
characterizing human embryonic stem cells are also
expressed by bone marrow MSCs. Our studies have shown
that MSCs did not express the pluripotency gene trio
Fig. 1 Gene network controlling bone marrow MSC proliferation. We
selected 64 transcripts that were downregulated after adipocytic,
osteoblastic and chondrocytic differentiation [3]. Ingenuity software
allowed to determine the network with the highest score (score of 46,
including 21 focus molecules effectively detected in the MSCs out of
30 molecules belonging to the theoretical network). Focus molecules
are indicated by filled symbols
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OCT4/POU5F1, NANOG and SOX2 [3, 4, 7]. The OCT4/
POU5F1 transcripts that were detected corresponded to
pseudogenes [7]. Other embryonic stem cell markers were
not detected, with the noticeable exception of the stage-
specific embryonic antigens 3 and 4 (SSEA-3, SSEA-4)
resulting from the activity in MSCs of the sialyltransferase
ST3GAL3 [4].
Differentiation Potential
As expected, we have shown that MSC clones differentiate
into the 3 mesenchymal lineages (osteoblastic, chondrocytic
and adipocytic). We have also shown that they differentiate
into the vascular smooth muscle cell lineage [3]. To induce
the full differentiation, cells were cultured for 21 days in the
long-term culture medium described for the generation and
maintenance of stromal cells associated to hematopoiesis,
since previous experiments had shown that bone marrow
stromal cells followed a vascular smooth muscle differen-
tiation pathway [8].
Previous studies performed outside Genostem [9, 10] have
shown that differentiation in the mesenchyme system is
reversible since apparently differentiated mesenchymal cells
are able to shift their differentiation pathway under modified
external conditions. This plasticity was exemplified in clones
where a switch was induced from the adipocytic to the
osteoblastic lineage or from hypertrophic chondrocytes to
osteoblasts. We have shown that this concept may be
extended to the vascular smooth muscle lineage since MSC
clones differentiated along this lineage can still differentiate
into osteoblasts, chondrocytes and adipocytes when further
cultured in osteo, chondro or adipogenic conditions [3].
Self-renewal
One of the key questions that have remained open for decades
about the biology ofMSCs is whether they are capable of self-
renewal, thus qualifying as bona fide stem cells rather than
simply multipotent cells. Identification of the in situ counter-
part of bone marrow MSCs as CD146-expressing subendo-
thelial (mural) cells in sinusoids has allowed to show that
transplanted MSCs can reconstitute a compartment of mural
cells with phenotype and clonogenic ability identical to those
of the originally explanted cells. These data, and the
possibility to secondarily passage single clonogenic CD146+
progenitors, represent direct evidence in support of the ability
of bone marrow MSCs to self-renew in vivo, and therefore of
their identity as bona fide stem cells [6].
Lineage Priming
Lineage priming is a characteristic of stem cells whereby
undifferentiated self-renewing stem cells express a subset of
genes associated to the differentiation pathways to which
they can commit. Lineage priming appears to be one
major attribute of the paradigmal hematopoietic stem cell
and is also suggested to be a property of embryonic stem
cells. We have therefore evaluated whether lineage
priming is also an attribute of bone marrow MSCs. We
have shown that fast-growing clones initiated at culture
inception are primed to the osteoblastic, chondrocytic,
adipocytic and vascular smooth muscle lineages, but not
to skeletal muscle, cardiac muscle, hematopoietic, hepato-
cytic or neural lineages [3].
Native Bone Marrow MSCs
Many hypotheses on the in situ original cells from which
MSCs descend have been raised. Some investigators have
suggested a non mesodermal, neuroectodermal origin [11];
others have suggested that hematopoietic stem cells could
generate mesenchymal cells [12]. Our studies have shown
that native bone marrow MSCs constitute a specialized,
tissue-specific subset of subendothelial, mural cells (peri-
cytes) essential for the establishment of the hematopoietic
microenvironment [6, 13]. Since pericytes belong to the
vascular smooth muscle cell family, these data are in
agreement with the vascular smooth muscle differentiation
potential of the culture-amplified cells. Markers of bone
marrow mural cells/pericytes can be used to prospectively
isolate bone marrow MSCs, which can further be shown i)
to contribute to the organization of microvascular structures
in vivo and of their surrogates in vitro, ii) to express a broad
range of mural cell markers in culture, and iii) to be
regulated by known regulators of microvessel assembly and
maturation [6]. In addition to CD146 and CD105 [6],
additional markers such as CD73, and CD200 [5] expressed
in a minor population of bone marrow mononuclear cells
(comprising 0,15–2% of the total number) can be used to
isolate clonogenic bone marrow MSCs. Expression of these
markers of uncultured cells is retained in non-differentiated
cells in culture, and then is variably modulated upon
induction of differentation.
Conclusions
The data collected during the Genostem project define bone
marrow MSCs as adult tissue stem cells which are : 1)
deriving from a subset of mural cells of bone marrow
sinusoids, 2) self-renewing, 3) quadripotential and selec-
tively primed to the mesenchymal and vascular smooth
muscle lineages, 4) flexible in their differentiation options
(mesenchyme plasticity), and 5) able to transfer and
organize the hematopoietic microenvironment . The Gen-
ostem project has begun to unravel some of the key
molecules that underly these specific properties.
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Differentiation Pathways
Genetic programs for osteo and chondrogenesis are
partially deciphered. In particular, the master transcription
factor RUNX2 is known to be the essential inducer of
osteoblastic differentiation, and the Sox trio, SOX5, SOX6
and SOX9, appears to play a similar role in chondrogenesis.
However, the description of the different molecules and
pathways operative in these differentiations is far from
complete. Little is known concerning the generation of
tenocytes since these cells are obtained only after implan-
tation in vivo of the cultured MSCs. Genostem teams have
therefore searched for novel inducers of osteo, chondro-
genesis and tenogenesis that may serve as bases for
innovative therapies in regenerative medicine.
Osteogenesis
Recent advances have been made to isolate and expand
MSCs from human bone marrow and to identify the
mechanisms that are responsible for the osteogenic differ-
entiation of these cells [14]. A better understanding of the
osteogenic differentiation program of MSCs is however
required in order to develop optimal strategies to promote
osteogenesis. The Genostem program offered the possibility
to study the transcriptome of human bone marrow MSCs
before and after osteoblastic differentiation. Transcription
profiles were analyzed according to published standards
(PMID: 19265543) and are available via www.bioretis.de.
We have then evaluated the osteogenic potential of selected
genes engineered in human primary MSCs in the preclinical
model of long bone repair in immunodeficient mice. Major
results of these studies are reported below.
FHL2 Promotes the Osteogenic Potential of Human Bone
Marrow MSCs
In murine and human bone marrow MSCs, we have
identified FHL2, a LIM-domain protein with four-and-a-
half Lim domains, as an early transcriptional cofactor that is
upregulated at early stages of osteoblastic differentiation
induced by dexamethasone. We showed that over-
expression of FHL2 increased osteoblastic marker gene
expression as well as in vitro osteogenesis. We further
showed that silencing of FHL2 abolished the stimulatory
effect of dexamethasone on RUNX2 and type I collagen. To
investigate how FHL2 may promote osteoblastic differen-
tiation, we showed that FHL2 interacts with catenin beta1
and promotes catenin beta1 nuclear translocation and
transcriptional activity, which indicates that Wnt/catenin
signaling is a critical mechanism involved in the positive
effect of FHL2 on osteoblastic differentiation in MSCs
[15]. Finally, we have shown that human MSCs over-
expressing FHL2 produced 2 times more bone than control
cells when implanted with a biomaterial in a standard
ectopic subcutaneous implantation assay in immunodefi-
cient mice (unpublished data). Overall, these findings
suggest a strategy targeted to FHL2 to promote osteogen-
esis in human bone marrow MSCs.
FGF-18 is an Essential Positive Regulator
of the Osteoblastic Differentiation Program in Murine
Bone Marrow MSCs
In murine bone marrow MSCs, we have found that
fibroblast growth factor 18 (FGF-18) was upregulated by
dexamethasone during osteoblastic differentiation. Over-
expression of FGF-18 by lentiviral infection, or treatment
of MSCs with recombinant human FGF-18 (rhFGF18),
induced the expression of receptor 2 of FGF-2 (FGFR2),
RUNX2 and downstream osteoblastic markers, and induced
in vitro osteogenesis. Furthermore, FGF-18 appeared to
promote the osteoblastic differentiation via activation of
FGFR2 since downregulation of FGFR2 using lentiviral
shRNAs blunted the osteoblastic gene expression induced
by rhFGF18. Further biochemical and pharmacological
analyses showed that rhFGF18-induced osteoblastic marker
gene expression was mediated by mitogen-activated protein
kinase (MAPK) and phosphatidylinositol kinase (PI3K)
signaling pathways. Thus, FGF-18 is an essential positive
regulator of the osteoblastic differentiation program in
murine bone marrow MSCs. Demonstration of a similar
role in human bone marrow MSCs awaits further studies.
Activated Integrin Alpha 5 Promotes Human Bone Marrow
MSC Osteoblastic Differentiation and Osteogenesis In Vivo
In human bone marrow MSCs, we have found that integrin
alpha5 (ITGA5) was upregulated by dexamethasone during
osteoblastic differentiation. Gain-of-function studies
showed that ITGA5 promoted the expression of osteoblastic
phenotypic markers as well as in vitro osteogenesis; in
contrast, loss-of-function studies using shRNAs showed
that downregulation of endogenous ITGA5 blunted the
osteoblastic marker gene expression and the osteoblastic
differentiation. Further molecular analyses showed that the
enhanced osteoblastic differentiation induced by ITGA5
was mediated by activation of focal adhesion kinase (FAK),
MAPK and PI3K signaling pathways. Remarkably, activa-
tion of endogenous ITGA5 using agonists that prime the
integrin was sufficient to activate MAPK and PI3K
signaling and to promote the osteoblastic differentiation
and in vitro osteogenesis. Additionally, we demonstrated
that MSCs engineered to overexpress ITGA5 exhibited a
marked increase in their osteogenic potential in vivo [16].
Taken together, these findings not only reveal that ITGA5 is
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required for osteoblastic differentiation of MSCs, but also
provide a novel targeted strategy using ITGA5 agonists to
promote the osteogenic capacity of these cells. This may be
used for tissue regeneration in bone disorders where the
recruitment or capacity of human bone marrow MSCs is
compromised.
Conclusions
In summary, our studies led to significant advances in the
mechanisms regulating bone marrow MSC osteoblastic
differentiation (Fig. 2). Specifically, progress has been
made in the identification of novel factors that govern and
promote human bone marrow MSC differentiation towards
functional osteogenic cells. This knowledge may result in
the development of innovative cell and gene therapeutic
strategies to promote bone repair.
Chondrogenesis
The major limitations of cell therapy applications of MSC
differentiated to chondrocytes are due to the lack of specific
differentiation factor and to the cell hypertrophy after
implantation in vivo. Genostem has offered the opportunity
to study on a large scale the factors involved in chondrocyte
biology.
One of the major results has been the identification of
new transcription factors involved in early stage chondro-
genic differentiation [17]. Among 1354 differentially
regulated genes during chondrogenesis induced from
human bone marrow MSCs, 705 were up-regulated. We
first focused our attention on forkhead box protein O1
(FOXO1A) which was shown, using RT-PCR, to be
increased by 6-fold as soon as day 2. We demonstrated
that FOXO1A was sufficient to induce chondrogenesis. For
this, we derived stable clones of the MSC murine
embryonic line C3H10T1/2 over-expressing either wild-
type or a constitutively active form of FOXO1A. After
21 days of culture in micropellet without any differentiation
factor, we could show the up-regulation of aggrecan,
collagen IIB and the down-regulation of collagen I. The
engineered cells cultured in specific inducing conditions did
not show higher osteogenic potential than naive cells and,
even more interestingly, showed lower adipogenic poten-
tial. After injection of the engineered cells in the intra-
articular space of knee joints, we could detect the formation
of cartilage, staining positive for aggrecan and collagen II,
in the areas of engineered cell injection, thus confirming
their potential to differentiate into chondrocytes.
In another work [18], we studied the cartilaginous
microenvironment generated by chondrocytes derived from
human bone marrow MSCs. The data obtained through
large-scale Taqman Low-Density Array based on qRT-PCR
have been assembled into a biological process-oriented
database that represents the first molecular profile of a
cartilaginous MSC niche. It included secreted cysteine-rich
regulatory proteins (CCNs), matrix metalloproteinases
(MMPs), members of the disintegrin and metalloproteinase
Fig. 2 Major lineage-
determining effectors in MSCs.
Lineages are regulated to a
considerable extent by members
of the TGF-β superfamily of
growth factors activating down-
stream Smad signaling media-
tors. This is a modified diagram
from [44]. Abbreviations: BMP:
bone morphogenetic protein; C/
EBP: CCAAT/enhancer binding
protein; GDF: growth and dif-
ferentiation factor; MRTF:
myocardin-related transcription




2; Sox5/6/9: SRY (sex determin-
ing region Y)-box 5, -box 6, -
box 9; SRF: serum response
factor; TGF-β: Transforming
growth factor-β
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domain-containing protein family (ADAMs) and cell
adhesion molecules (CAMs including cadherins). CCNs
interact with growth factors and have important functions in
cell proliferation and differentiation. CCN3, CCN4 and
CCN5 were upregulated after differentiation whereas CCN1
and CCN6 were down-regulated. The timely degradation of
the ECM is an important feature of development, morpho-
genesis and remodelling and is mainly mediated by MMPs.
Only MMP2 and MMP9 were present in MSCs before and
after differentiation, and MMP7, MMP3 and MMP28,
which were not expressed in MSCs before differentiation,
were highly up-regulated during chondrogenic differentia-
tion. ADAMs interact with various partners such as
integrins, syndecans and ECM proteins due to their role in
cell-ECM interaction. ADAM8, ADAM9, ADAM19, AD-
AM23, ADAMTS4 and ADAMTS5 were expressed in MSCs.
CAMs have important functions in development and tissue
morphogenesis. CDH2 (N-cadherin), CDH4 and CDH13
were expressed in MSCs and all were decreased in
chondrogenic differentiated cells. CDH11 (OB-cadherin),
NRCAM and MCAM/CD146 were up-regulated for more
than 30 fold by day 21 of chondrogenesis. Integrins act by
transmitting signals from the ECM to the cellular machin-
ery, resulting in changes in cell function. ITGA5, ITGA7,
ITGA10 and ITGAE were expressed in non differentiated
MSCs with high increase of ITGA6 by day 21 of
chondrogenic differentiation.
Because chemokines and cytokines are thought to play
an important role in cell activation, survival and differen-
tiation, we analysed the data obtained from the tran-
scriptome study and found that CCL2, CXCL12 and
FLT3L were all down-regulated after chondrogenesis. In
contrast we observed a significant increase of CCR1,
CCR3, CCR4 and CXCR4 [18].
In a synthesis work on the transcriptome [19], we were
able to describe a 3-step differentiation process. The first
step corresponded to trancripts implicated in cell attach-
ment and induction of apoptosis, the second step was
characterized by transcripts implicated in proliferation/
differentiation, and the third step was characterized by
transcripts implicated in chondrocytic differentiation and/or
hypertrophy.
In summary, our studies led to significant progress in the
identification of the molecular microenvironment associat-
ed to the chondrocytic differentiation of MSCs, and in the
molecular characterization of this differentiation (Fig. 2).
Tenogenesis
Until the present time, therapeutic options used to repair
tendon and ligament injuries have consisted in autografts,
allografts or synthetic prostheses [20]. None of these
alternatives, however, has provided a successful long-term
solution. In Genostem we developed the hypothesis that a
potent inducer of tenocytic differentiation of MSCs might
result in a novel and powerful modality for tendon repair.
We have identified such an inducer in Smad8, a signaling
mediator of the transforming growth factor beta/bone
morphogenic protein (TGF-beta/BMP) family of growth
factors [21]. We characterized the role of Smad8 in the
tendon differentiation pathway after forced expression of the
biological active form of Smad8 in the well-studied murine
MSC line C3H10T½ and in human bone marrow MSCs. A
genome-wide analysis of gene expression during Smad8-
dependent tenogenic differentiation has resulted in several
candidate genes potentially involved in tenogenic differenti-
ation program. Characterization of these factors is under
investigation (Nuber, Häupl and Gross, in preparation).
In conclusion, we have pinpointed a pathway for tendon/
ligament formation (Fig. 2).
Preclinical Studies in Animal Models
Another large part of Genostem activity has been devoted
to studies of the repair capacity of MSCs in animal models,
a prerequisite for future clinical trials. Work has been done
to develop innovative biomaterials and to test the ability of
MSC/biomaterial constructs to repair bone, cartilage and
tendons.
Biomaterials
The Genostem consortium enabled developing various
biomaterials tailored for specific applications in bone,
cartilage and tendon repair. The biomaterials were devel-
oped and tested with bone marrow MSCs both in vitro and
in vivo. The proposed biomaterials followed two major
research lines: biomaterials with fast translation into the
clinic and innovative biomaterials with a longer path to
reach the clinical applications. Those strategies were
pursued as complementary routes.
A new set of biodegradable biomaterials was developed
by combining chitosan, a polysaccharide, with various
biodegradable aliphatic polyesters. Those materials were
intended to combine the good biological performance of
chitosan with the melt processability of the polyesters. The
materials were thoroughly characterized in terms of mor-
phology, mechanical properties and kinetics of biodegrada-
tion showing excellent performance compatible with the
application in bone and cartilage [22]. The biological
performance was evaluated in vitro using the mouse bone
marrow MSC line BMC9 [23, 24]. The combination of
chitosan with poly(butylene succinate), in a equal fraction
by weight (chitosan/PBS), showed high cell viability.
Porous structures were shown to support viable cultures
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of BMC9. This biomaterial was compatible with the
successful in vitro differentiation of BMC9 into the lineages
of interest, expressing osteoblastic or chondrocytic genes
depending on the medium used to differentiate the cells.
Further work developed with primary human bone marrow
MSCs confirmed the osteoinductive capacity of the scaf-
folds [25].
In vivo study of bone marrow MSC-scaffold combina-
tions has been performed using non-invasive in vivo
photonic imaging. Different scaffolds (PEG-RGD,
gelatine-hydrogel, calcium alginate beads) were loaded
with cells expressing luciferase gene reporter and were
ectopically transplanted both subcutaneously and intramus-
cularly in animal models. Results have shown that
intramuscular transplants were viable for up to 90 days,
thus providing a safe method for monitoring localization
and viability of transplanted cells following in vivo
transplantation [26].
In summary, we have developed a set of novel scaffolds
and procedures that will be useful for the repair of both
bone and cartilage in the presence of MSCs.
Bone Repair
For evaluation of the in vivo osteogenic functionality of
MSCs, cell-scaffold constructs were transplanted in femoral
bone defects in immunodeficient mice. Cells were isolated
and expanded according to the Genostem protocol. Fol-
lowing osteogenic differentiation, cells were loaded onto
fibrin/ceramic constructs and transplanted in athymic nude
mice. After eight weeks tissue samples were processed for
histology and immunohistochemistry. Previous results have
shown that subcutaneous transplants of cell/ceramic con-
structs resulted in ectopic bone formation [27]. When the
same cell-scaffold constructs were implanted in femoral
critical size defect we observed, 8 weeks after transplanta-
tion, bone formation in place of fibrous tissue, as shown in
Fig. 3a and b (Srouji et al. preliminary results).
Cartilage Repair
Clinical application of MSC-differentiated chondrocytes in
rheumatic disease like osteoarthrirtis (OA) requires appro-
priate scaffolds that are chondro-inductive, bio-resorbable
and non inflammatory, and are adapted for intra-articular
injection. Genostem offered the opportunity to test in vivo
different scaffolds combined with human bone marrow
MSCs.
In order to deliver the growth factor TGF-beta3 (TGFb3)
in a controlled manner we developed microparticles with a
bio-mimetic surface of matrix molecules (Pharmacologically
Active Microcarriers or PAM). We selected a combination of
fibronectin (FN) and poly-D-lysine as the best bio-mimetic
Fig. 3 Connective tissue repair by MSCs. a, b Orthotopic bone
repair. Segmental critical size bone defect (2 mm) created in femoral
midshaft of athymic nude mice; the defect was filled with MSC-
ceramic transplant. a Defect in the absence of grafting; note the
presence of fibrous tissue filling the gap. b Bone reconstruction
(8 weeks after engraftment) was apparent in place of the fibrous tissue
(arrow). c, d Orthotopic cartilage repair. Large size defect was
created in the patella of Merinos sheep. Autologous bone marrow
MSCs were harvested and expanded in culture for 2 passages, before
being seeded in fibrin clots or scaffolds of chitosan + TGFb3. The
material was implanted in the patella defect. Animals were left in the
field for 8 weeks before sacrifice. C. lesions filled with ovine MSC in
fibrin clot. d Lesions filled with ovine MSCs embedded in chitosan
scaffolds + TGFβ3. Arrows indicate the junction between endogenous
and new tissues. e Heterotopic tendon formation. The intramuscular
transplantation of adenovirally modified MSCs (C3H10T1/2 embry-
onic cell line) expressing Smad8 and Bmp2 leads, 4 weeks after
implantation, to the heterotopic formation of tendinous elements
(hematoxylin and eosin staining). The tendinous element (shown
within the black and white arrowheads) is characterized by a tendon-
typical crimp pattern and flattened tenocyte-like cells. Abbreviations:
B, bone; M, muscle; T, tendon
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surface. The cell adhesion protocol has been completed
by an overnight cell culture step necessary to obtain the
formation of PAM and cell aggregates. When MSCs
were cultured in presence of PAM-TGFb3, cells rapidly
adhered onto the PAMs and progressively aggregated to
form a unique pellet-like structure from day 7 to day 21.
In PAM-TGFb3-induced aggregates, high expression of
chondrogenic markers occurred in a time-dependent
manner whereas expression of osteogenic and adipogenic
markers was lower than those observed when PAM-FN
were used. Intra-articular injection of MSCs mixed with
PAM-TGFb3 confirmed their capacity to form a neotissue
with characteristics of cartilage.
We used the ovine model of cartilage repair to
demonstrate the capacity of bone marrow MSCs combined
with fibrin clot ± chitosan/PBS scaffolds and TGFb3 to
induce cartilage tissue in a preclinical model [28]. Ovine
MSCs were shown to display the three main characteristics
of MSCs: adherence to plastic, characteristic phenotypic
profile (positive for CD44, CD105 and vimentin, and
negative for CD34 and CD45) and trilineage differentiation
potential. Ovine MSCs, either in fibrin clot alone or with
chitosan ± TGFβ3, were able to repair a partial-thickness
defect in the cartilaginous tissue of sheep patella (Fig. 3c
and d).
Tendon Repair
The strategies for MSC-mediated tendon repair was based
on the Smad8-dependent tenogenic differentiation model
described above. Tissue regeneration of a rat achilles
tendon partial-defect model, using C3H10T1/2 MSCs
expressing Smad8 and BMP-2 was demonstrated [21]. We
observed the formation of fibrous ligament-to-bone and
tendon-to-bone interfaces (“entheses” or osteotendinous
junctions) after heterotopic implantation of the genetically
engineered MSC line in muscle tissue as shown of Fig. 3e.
Entheses serve to dissipate stress between soft tissue and
bone and surgical reconstruction of these interfaces is an
issue of considerable importance. Entheses are prone to
injury and the integration of bone and tendon/ligament is in
general not satisfactory. Our findings should eventually
contribute to the establishment of MSC-dependent regener-
ative therapies for tendon-bone insertions (Shahab-Osterloh,
et al, under revision).
Moreover, a novel method was devised to quantify in
vivo tendon biomechanics by minimally invasive proce-
dures establishing endoscopic fibered confocal fluorescence
microscope images of externally loaded tendons. Through a
series of image post-processing steps, cellular displace-
ments may be reduced to tissue strains, giving a quantifi-
able estimate of the functional integrity of the tendon
tissues [29–31]. These methods may enable to assess the
impact on normal tendon homeostasis and healing process-
es by minimally invasive procedures.
Conclusions and Perspectives
Concerning bone marrow MSC biology, work performed in
Genostem has has helped solve three major problems. We
now know 1) where the native cells are located (on the
abluminal side of endothelial cells of sinuses) and how to
select them, 2) that stromal cells forming the niche of
hematopoietic stem cells and bone marrow MSCs are the
same entity, thus resolving a long-standing issue, and 3)
that clonal highly proliferative culture-amplified cells are
bona fide stem cells since sharing with the other paradigmal
adult stem cells, the hematopoietic stem cells, two major
properties, that of self-renewal and that of multipotential
priming. Many issues remain to be solved. Are MSCs also
primed to the tenogenic lineage ? Is it possible to describe for
the MSC system a hierarchy among precursors that would
discriminate between self-renewing multipotential MSCs and
progenitors/transit amplifying cells devoid of self-renewal
capacity, and more restricted in their differentiation ability
(note that such “classical” model for stem cell differentiation
in other systems is presently under much debate [32, 33]) ? Is
the self-renewal capacity of MSCs comparable to that of
hematopoietic stem cells (sequential transplantations would
solve this problem) ? Would cross-inhibitory loops between
transcription factors account for multipotential lineage
priming in MSCs, as suggested for hematopoietic or
embryonic stem cell lineage priming [34] ? Does the
reprogrammation of MSCs into non primed lineages [35,
36] implies reversion to pluripotent cell stage as described
for skin fibroblasts [37], or is true transdifferentiation
possible [38]? What is the influence of the surrounding
matrix and biomechanical stress on lineage priming and
programming/reprogramming of MSCs [39]?
Genostem identified and developed a set of new
biomaterials and scaffolds that showed adequate perfor-
mance in vivo for the repair of bone and cartilage. The
cohort of biomaterials and scaffolds proposed by Genostem
continues being developed towards pre-clinical testing for
the repair of connective tissues aiming at reaching the
clinical testing stage.
Concerning bone repair, work performed in Genostem led
to identify novel genes and factors that promote MSC
osteogenic differentiation and osteogenesis in vitro and in
vivo. Future studies, now ongoing, will determine whether
some of these genes or factors can be used to promote bone
repair in preclinical settings. Ongoing studies are also aimed
at identifying other genes and proteins that are upregulated
during MSC osteogenic differentiation and can be used to
promote the osteogenic and bone repair processes.
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Concerning cartilage repair, work performed in Genos-
tem opens perspectives for the cell therapy of disorders
including cartilage defect and cartilage damage related to
arthritis/osteoarthitis. However, results in the long term
evaluating integration of the newly formed tissue with the
native cartilage need to be obtained before large application
in clinical practice can be envisioned.
Concerning tendon repair, identification of the signalling
molecules implicated in tenogenesis has been a major step
forward. Future studies will determine how this newly-
acquired knowledge may be applied to preclinical models
using human bone marrow MSCs, before considering
clinical application in cases of tendon rupture.
Whatever the site of repair, the mechanisms of repair
still need to be elucidated. A traditional view would be
that the transplanted donor MSCs migrate to the injured
site where they proliferate and differentiate into appro-
priate cells (osteoblasts, chondrocytes or tenocytes
pending on the injured tissue). An alternative view
would be that MSCs provide growth factors helping in
situ host MSCs to proliferate and differentiate. Such
trophic effect has been recently shown in an animal
model of fracture healing [40] and is suggested to be the
major mechanism to explain the beneficial role of MSC
administration in non-orthopedic-related disorders such as
vascular repair [41].
A last important issue is whether bone marrow MSCs are
identical to other connective-tissue forming cells not found
in bone marrow (adipose tissue, umbilical cord vessel,
Wharton’s jelly, placenta…). Many authors suggest this to
be the case, the major arguments being the similarity of
phenotype and of differentiation capacity (into osteoblasts,
chondrocytes, adipocytes and even myocytes) between cells
derived from bone marrow and other tissues [42]. Data
from Genostem contradict this hypothesis stressing that
bone marrow MSCs present unique properties : specific
expression of certain membrane antigens, unique ability to
form bone and transfer the hematopoietic microenviron-
ment in vivo after transplantation to ectopic sites, specific
transcriptomic profile… [5–7, 43]. Further studies should
more closely discriminate the connective-tissue stem cell
types with regard to their tissue of origin.
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